Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer

Completed · Phase 2

Conditions studied: Squamous Cell Carcinoma of the Head and Neck

In brief

This phase two trial will determine the tumor response rate at the primary site and at involved regional nodes to two cycles of an IC regimen of weekly Abraxane and cetuximab given in combination with cisplatin and 5-FU in patients with local regionally advanced HNSCC.

Key facts

Study ID

NCT00736944

Run by

Washington University School of Medicine

People needed

30

Starts

2008-12-19

Expected to finish

2020-07-06

Last updated by the study team

2020-09-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Peripheral neuropathy > Grade 1.
• Prior chemotherapy, EGFR targeted therapy or radiation therapy for HNSCC.
• History of prior invasive malignancy diagnosed within the last three years other than local stage non-melanoma skin cancer.
• Be taking cimetidine or allopurinol. Patients must discontinue taking the medication for one week before receiving treatment with Abraxane.
• Be taking cimetidine or allopurinol. Patients must discontinue taking the medication for one week before receiving treatment with Abraxane.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.